Home/Pipeline/APG808

APG808

Asthma

Phase 1bInterim results reported

Key Facts

Indication

Asthma

Phase

Phase 1b

Status

Interim results reported

Company

Apogee Therapeutics

About Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotech with a mission to reshape the standard of care in inflammatory and immune (I&I) diseases by developing superior, half-life extended antibody therapies. Its lead asset, zumilokibart (APG777), an anti-IL-13, has shown positive Phase 2 data in atopic dermatitis and is advancing in asthma and eosinophilic esophagitis. The company's strategy leverages a proprietary FcRn engineering platform to create less frequent dosing regimens and is pursuing both monotherapy and novel combination approaches to capture significant share in large, validated markets.

View full company profile

Therapeutic Areas

Dermatology Pulmonology Gastroenterology Immunology

Other Asthma Drugs

Drug	Company	Phase	Status
Technegas® for Asthma	Cyclomedica	Phase 2	Active
Asthma Candidate	Teva	Phase 3	Active
Montelukast Amorphous Form	Morepen Laboratories	Phase-2	Active
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
RIG-101	RIGImmune	Pre-clinical	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
Asthma Trial	Science 37	Phase 3	Completed/Highlighted
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Digital Biomarker for Asthma	electronRx	Early Development	Active